Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Wirden

Showing results (51-60 of 98) with videos related to

Pageof 10
Sort By:
The Journal of Antimicrobial Chemotherapy|April 9, 2011
Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patientsIsabelle Malet, Marc Wirden, Slim Fourati, et al.
AIDS (London, England)|January 10, 2014
Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse anatomical compartmentsSlim Fourati, Sidonie Lambert-Niclot, Cathia Soulie, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|September 27, 2017
Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral loadMarc Wirden, Lucile Larrouy, Nadia Mahjoub, et al.
The Journal of Antimicrobial Chemotherapy|July 15, 2026
Clearance of NNRTI resistance-associated mutations in the HIV-1 DNA reservoir with or without the presence of M184V mutationCathia Soulie, Karen Zafilaza, Marc Wirden, et al.
Antimicrobial Agents and Chemotherapy|February 2, 2011
Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavirLucile Larrouy, Sidonie Lambert-Niclot, Charlotte Charpentier, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|January 31, 2016
Performance of genotypic algorithms for predicting tropism of HIV-1CRF02_AG subtypeC Soulié, D B Fofana, N Boukli, et al.
Journal of Medical Virology|July 20, 2004
Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patientsAnne-Geneviève Marcelin, Dissou Affolabi, Claire Lamotte, et al.
The Journal of Antimicrobial Chemotherapy|July 6, 2012
Risk factors for raltegravir resistance development in clinical practiceIsabelle Malet, Slim Fourati, Laurence Morand-Joubert, et al.
Antimicrobial Agents and Chemotherapy|January 30, 2008
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitroIsabelle Malet, Olivier Delelis, Marc-Antoine Valantin, et al.
The Journal of Antimicrobial Chemotherapy|July 23, 2013
Highly multidrug-resistant HIV: clonal analysis and therapeutic strategiesEve Todesco, Sophie Sayon, Slim Fourati, et al.
Pageof 10

Showing results (51-60 of 98) with videos related to

Sort By:
Pageof 10
The Journal of Antimicrobial Chemotherapy|April 9, 2011
Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patientsIsabelle Malet, Marc Wirden, Slim Fourati, et al.
AIDS (London, England)|January 10, 2014
Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse anatomical compartmentsSlim Fourati, Sidonie Lambert-Niclot, Cathia Soulie, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|September 27, 2017
Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral loadMarc Wirden, Lucile Larrouy, Nadia Mahjoub, et al.
The Journal of Antimicrobial Chemotherapy|July 15, 2026
Clearance of NNRTI resistance-associated mutations in the HIV-1 DNA reservoir with or without the presence of M184V mutationCathia Soulie, Karen Zafilaza, Marc Wirden, et al.
Antimicrobial Agents and Chemotherapy|February 2, 2011
Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavirLucile Larrouy, Sidonie Lambert-Niclot, Charlotte Charpentier, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|January 31, 2016
Performance of genotypic algorithms for predicting tropism of HIV-1CRF02_AG subtypeC Soulié, D B Fofana, N Boukli, et al.
Journal of Medical Virology|July 20, 2004
Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patientsAnne-Geneviève Marcelin, Dissou Affolabi, Claire Lamotte, et al.
The Journal of Antimicrobial Chemotherapy|July 6, 2012
Risk factors for raltegravir resistance development in clinical practiceIsabelle Malet, Slim Fourati, Laurence Morand-Joubert, et al.
Antimicrobial Agents and Chemotherapy|January 30, 2008
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitroIsabelle Malet, Olivier Delelis, Marc-Antoine Valantin, et al.
The Journal of Antimicrobial Chemotherapy|July 23, 2013
Highly multidrug-resistant HIV: clonal analysis and therapeutic strategiesEve Todesco, Sophie Sayon, Slim Fourati, et al.
Pageof 10